Mayor Lee Announces Pfizer to Establish Premiere Research Center in San Francisco
Pfizer Signs Lease for Center for Therapeutic Innovation in Mission Bay, Becoming the City’s 75th Life Sciences Firm
07/22/11—Mayor Edwin M. Lee today announced that Pfizer, the world’s largest biopharmaceutical company, will locate their Center for Therapeutic Innovation (CTI) in the Mission Bay redevelopment area. Pfizer’s research center will be located at 1700 Owens Street and can accommodate up to 40 researchers, which will be a mix of Pfizer CTI scientists and academic collaborators. This decision follows Pfizer’s announcement last year selecting the University of California, San Francisco (UCSF) as the first CTI partnership. Pfizer’s total potential investment in research in San Francisco could be as much as $100 million. Pfizer marks the City’s 75th life sciences firm.
“Pfizer’s Center for Therapeutic Innovation will serve as a cornerstone of San Francisco’s burgeoning biotech cluster,” said Mayor Lee. “This move brings the world’s largest biopharmaceutical company to Mission Bay, creates dozens of new jobs, and affirms San Francisco’s role as the location of choice for top life sciences companies. Congratulations to Pfizer and UCSF on the innovative partnership which laid the groundwork for this move.”
“The Centers for Therapeutic Innovation is a collaboration combining the unique advantages of top academic research institutions with Pfizer's leading drug development capabilities and research technologies to more quickly move to novel discoveries and targets for future medicines. San Francisco is an important hub of academic excellence, and we are proud to build our presence here,” said Anthony Coyle, Ph.D., Vice President and Head of Pfizer’s Global Centers for Therapeutic Innovation. “UCSF is a world-class medical center with a strong focus on both basic science and clinical research. Ultimately, we believe enabling UCSF and Pfizer scientists to work side-by-side could create significant benefit for the patient, for investigators, and for each institution.”
“This is a greatly welcomed development that showcases the real strength of Mission Bay and UCSF in bringing together key players in bioscience,” said UCSF Executive Vice Chancellor Jeffrey A. Bluestone, Ph.D. “Pfizer is an invaluable research partner for UCSF. Having them right across the street will strengthen our collaboration even further on projects that can offer real hope to patients in the future.”
Pfizer has sub-leased space for CTI San Francisco from the Gladstone Institutes and plans to occupy in the next few weeks. The location was selected to facilitate optimal collaboration by being so closely located to UCSF.
“We are delighted to have Pfizer moving in,” said Warner C. Greene, M.D., Ph.D., who directs all virology and immunology research at Gladstone, an independent biomedical-research organization. “Proximity leads to progress—having outstanding pharmaceutical colleagues of this caliber at Mission Bay can only enrich Gladstone’s ability to translate basic research into health solutions for patients in need.”
Mission Bay is a 303-acre redevelopment project designed from the ground up as a model for mixed-use, transit oriented and sustainable development. At full build-out, Mission Bay will include 6,000 new housing units, more than four million square feet of lab and office space and 43 acres of new public parks. The area is served by the T-Third Muni Metro Line and will include more than $700 million dollars of new public infrastructure including roads and utilities. Mission Bay is home to UCSF’s Mission Bay Research Campus and the future $1.5 billion UCSF Medical Center at Mission Bay. The Medical Center will include the UCSF Benioff Children’s Hospital, the UCSF Women’s Specialty Hospital and the UCSF Cancer Hospital and is scheduled to open in 2014.
Mission Bay is home to more than 35 life sciences firms. Pfizer becomes the third major pharmaceutical company to locate in Mission Bay, along with Merck and Bayer.
07/22/11—Mayor Edwin M. Lee today announced that Pfizer, the world’s largest biopharmaceutical company, will locate their Center for Therapeutic Innovation (CTI) in the Mission Bay redevelopment area. Pfizer’s research center will be located at 1700 Owens Street and can accommodate up to 40 researchers, which will be a mix of Pfizer CTI scientists and academic collaborators. This decision follows Pfizer’s announcement last year selecting the University of California, San Francisco (UCSF) as the first CTI partnership. Pfizer’s total potential investment in research in San Francisco could be as much as $100 million. Pfizer marks the City’s 75th life sciences firm.
“Pfizer’s Center for Therapeutic Innovation will serve as a cornerstone of San Francisco’s burgeoning biotech cluster,” said Mayor Lee. “This move brings the world’s largest biopharmaceutical company to Mission Bay, creates dozens of new jobs, and affirms San Francisco’s role as the location of choice for top life sciences companies. Congratulations to Pfizer and UCSF on the innovative partnership which laid the groundwork for this move.”
“The Centers for Therapeutic Innovation is a collaboration combining the unique advantages of top academic research institutions with Pfizer's leading drug development capabilities and research technologies to more quickly move to novel discoveries and targets for future medicines. San Francisco is an important hub of academic excellence, and we are proud to build our presence here,” said Anthony Coyle, Ph.D., Vice President and Head of Pfizer’s Global Centers for Therapeutic Innovation. “UCSF is a world-class medical center with a strong focus on both basic science and clinical research. Ultimately, we believe enabling UCSF and Pfizer scientists to work side-by-side could create significant benefit for the patient, for investigators, and for each institution.”
“This is a greatly welcomed development that showcases the real strength of Mission Bay and UCSF in bringing together key players in bioscience,” said UCSF Executive Vice Chancellor Jeffrey A. Bluestone, Ph.D. “Pfizer is an invaluable research partner for UCSF. Having them right across the street will strengthen our collaboration even further on projects that can offer real hope to patients in the future.”
Pfizer has sub-leased space for CTI San Francisco from the Gladstone Institutes and plans to occupy in the next few weeks. The location was selected to facilitate optimal collaboration by being so closely located to UCSF.
“We are delighted to have Pfizer moving in,” said Warner C. Greene, M.D., Ph.D., who directs all virology and immunology research at Gladstone, an independent biomedical-research organization. “Proximity leads to progress—having outstanding pharmaceutical colleagues of this caliber at Mission Bay can only enrich Gladstone’s ability to translate basic research into health solutions for patients in need.”
Mission Bay is a 303-acre redevelopment project designed from the ground up as a model for mixed-use, transit oriented and sustainable development. At full build-out, Mission Bay will include 6,000 new housing units, more than four million square feet of lab and office space and 43 acres of new public parks. The area is served by the T-Third Muni Metro Line and will include more than $700 million dollars of new public infrastructure including roads and utilities. Mission Bay is home to UCSF’s Mission Bay Research Campus and the future $1.5 billion UCSF Medical Center at Mission Bay. The Medical Center will include the UCSF Benioff Children’s Hospital, the UCSF Women’s Specialty Hospital and the UCSF Cancer Hospital and is scheduled to open in 2014.
Mission Bay is home to more than 35 life sciences firms. Pfizer becomes the third major pharmaceutical company to locate in Mission Bay, along with Merck and Bayer.